{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:35:28Z","timestamp":1792470928126,"version":"4.5.0"},"reference-count":223,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cca.2026.121066","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:56:16Z","timestamp":1778817376000},"page":"121066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders"],"prefix":"10.1016","volume":"590","author":[{"given":"Amr Ali Mohamed Abdelgawwad","family":"El-Sehrawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaleb","family":"Oriquat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sokhib","family":"Saidov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uktam","family":"Ruzikulov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulnora","family":"Shakhmurova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bnyn Jasb","family":"Jbl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Shefali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.cca.2026.121066_bb0005","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cca.2026.121066_bb0010","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamainternmed.2024.8124","article-title":"Diagnosis and Management of Monoclonal Gammopathy of undetermined significance: a review","volume":"185","author":"Liu","year":"2025","journal-title":"JAMA Int Med"},{"issue":"7","key":"10.1016\/j.cca.2026.121066_bb0015","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121066_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1045002","article-title":"Monoclonal gammopathies of clinical significance (MGCS): in pursuit of optimal treatment","volume":"13","author":"Oganesyan","year":"2022","journal-title":"Front. Immunol."},{"issue":"Suppl. 4","key":"10.1016\/j.cca.2026.121066_bb0025","first-page":"45","article-title":"A focus on Waldenstr\u00f6m Macroglobulinemia and AL amyloidosis","volume":"13","author":"Lu","year":"2022","journal-title":"J. Adv. Pract. Oncol."},{"issue":"12","key":"10.1016\/j.cca.2026.121066_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16122263","article-title":"The challenging approach to multiple myeloma: from disease diagnosis and monitoring to complications management","volume":"16","author":"Mor\u00e8","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0035","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network","volume":"99","author":"van de Donk","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.cca.2026.121066_bb0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1634\/theoncologist.2015-0303","article-title":"The changing landscape of smoldering multiple myeloma: a European perspective","volume":"21","author":"Caers","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/blood-2017-09-807560","article-title":"How I manage monoclonal gammopathy of undetermined significance","volume":"131","author":"Go","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0050","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clml.2021.07.028","article-title":"Management of Myeloma Manifestations and Complications: the cornerstone of supportive care: recommendation of the Canadian myeloma research group (formerly myeloma Canada research network) consensus guideline consortium","volume":"22","author":"LeBlanc","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0055","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1038\/bcj.2017.19","article-title":"Mutational landscape reflects the biological continuum of plasma cell dyscrasias","volume":"7","author":"Rossi","year":"2017","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.cca.2026.121066_bb0060","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3324\/haematol.2021.278519","article-title":"2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde","volume":"106","author":"Musto","year":"2021","journal-title":"Haematologica"},{"issue":"Suppl","key":"10.1016\/j.cca.2026.121066_bb0065","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.clml.2016.02.025","article-title":"Clonal evolution in multiple myeloma","volume":"16","author":"Fakhri","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"11","key":"10.1016\/j.cca.2026.121066_bb0070","article-title":"Advancements in multiple myeloma research: high-throughput sequencing technologies, omics, and the role of artificial intelligence","volume":"13","author":"Guti\u00e9rrez-Gonz\u00e1lez","year":"2024","journal-title":"Biology (Basel)"},{"issue":"8","key":"10.1016\/j.cca.2026.121066_bb0075","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and treatment of renal failure in multiple myeloma","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.cca.2026.121066_bb0080","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","article-title":"Imaging in multiple myeloma: how? When?","volume":"133","author":"Zamagni","year":"2019","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.cca.2026.121066_bb0085","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cca.2026.121066_bb0090","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/COC.0000000000001197","article-title":"Advancing MRD detection in multiple myeloma: technologies, applications, and future perspectives","volume":"48","author":"Chen","year":"2025","journal-title":"Am. J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.cca.2026.121066_bb0095","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-016-0336-4","article-title":"High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers\/probes","volume":"9","author":"Bai","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.cca.2026.121066_bb0105","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.cca.2026.121066_bb0110","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41375-024-02366-9","article-title":"Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma","volume":"38","author":"Yan","year":"2024","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.cca.2026.121066_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35960","article-title":"Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): perspectives from the MRD partnership and Alliance in AML clinical treatment consortium","volume":"131","author":"Boyiadzis","year":"2025","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.cca.2026.121066_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17030525","article-title":"The evolving landscape in multiple myeloma: from risk stratification to T cell-directed advanced therapies","volume":"17","author":"Besliu","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40364-020-0182-y","article-title":"Novel immunomodulatory drugs and neo-substrates","volume":"8","author":"Gao","year":"2020","journal-title":"Biomark. Res."},{"issue":"24","key":"10.1016\/j.cca.2026.121066_bb0130","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121066_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01613","article-title":"Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen","volume":"10","author":"Timmers","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121066_bb0140","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2021.39.15_suppl.8036","article-title":"Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study","volume":"39","author":"Manier","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.cca.2026.121066_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17152479","article-title":"Bispecific antibodies and antibody-drug conjugates in relapsed\/refractory aggressive non-Hodgkin lymphoma, focusing on diffuse large B-cell lymphoma","volume":"17","author":"Caserta","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cca.2026.121066_bb0150","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.2147\/JIR.S499403","article-title":"The benefits and safety of monoclonal antibodies: implications for cancer immunotherapy","author":"Zhang","year":"2025","journal-title":"J. Inflamm. Res."},{"issue":"20","key":"10.1016\/j.cca.2026.121066_bb0155","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal Gammopathy of renal significance","volume":"384","author":"Leung","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.cca.2026.121066_bb0160","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121066_bb0165","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/asheducation-2010.1.295","article-title":"Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology","volume":"2010","author":"Landgren","year":"2010","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"17","key":"10.1016\/j.cca.2026.121066_bb0170","article-title":"Monoclonal gammopathy of clinical significance (MGCS) and related disorders: a review and the role of imaging","volume":"14","author":"El Sadaney","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"10.1016\/j.cca.2026.121066_bb0175","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0180","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.cca.2026.121066_bb0185","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.cca.2026.121066_bb0190","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International myeloma society\/international myeloma working group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.cca.2026.121066_bb0195","article-title":"Clonal evolution of multiple myeloma-clinical and diagnostic implications","volume":"11","author":"Salomon-Perzy\u0144ski","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"17","key":"10.1016\/j.cca.2026.121066_bb0200","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1182\/blood.2020005885","article-title":"Progression signature underlies clonal evolution and dissemination of multiple myeloma","volume":"137","author":"Shen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121066_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101168","article-title":"Chromosomal defects in multiple myeloma","volume":"64","author":"Clarke","year":"2024","journal-title":"Blood Rev."},{"issue":"13","key":"10.1016\/j.cca.2026.121066_bb0210","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cca.2026.121066_bb0215","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/leu.2014.13","article-title":"Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma","volume":"28","author":"Melchor","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0220","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ccell.2023.05.007","article-title":"Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease","volume":"41","author":"Dang","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.cca.2026.121066_bb0225","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.7150\/ijbs.92988","article-title":"The burgeoning significance of liquid-liquid phase separation in the pathogenesis and therapeutics of cancers","volume":"20","author":"Xu","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.cca.2026.121066_bb0230","series-title":"Cell Respiration and Cell Survival: Processes, Types and Effects, Nova Science Publishers","first-page":"94","article-title":"The bone marrow microenvironment in multiple myeloma: Cellular and molecular basis of disease progression","author":"Ria","year":"2010"},{"key":"10.1016\/j.cca.2026.121066_bb0235","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/bs.ircmb.2014.10.004","article-title":"Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis","volume":"314","author":"Ribatti","year":"2015","journal-title":"Int. Rev. Cell Mol. Biol."},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020613","article-title":"Bone marrow stromal cells-induced drug resistance in multiple myeloma","volume":"21","author":"Ria","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.cca.2026.121066_bb0245","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41568-020-0245-2","article-title":"Bone marrow niches in haematological malignancies","volume":"20","author":"M\u00e9ndez-Ferrer","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0250","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0255","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","volume":"13","author":"Vo","year":"2022","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.cca.2026.121066_bb0260","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood.2023019758","article-title":"Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis","volume":"142","author":"Poos","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121066_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtbi.2023.111652","article-title":"Phenotype-structured model of intra-clonal heterogeneity and drug resistance in multiple myeloma","volume":"576","author":"Bouchnita","year":"2024","journal-title":"J. Theor. Biol."},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0270","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/blood-2004-11-4286","article-title":"The FA\/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells","volume":"106","author":"Chen","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cca.2026.121066_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030504","article-title":"DNA damage response in multiple myeloma: the role of the tumor microenvironment","volume":"13","author":"Saitoh","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0280","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.cca.2026.121066_bb0285","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1182\/blood-2005-10-009084","article-title":"ABCG2 expression, function, and promoter methylation in human multiple myeloma","volume":"108","author":"Turner","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cca.2026.121066_bb0290","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/sj.leu.2404859","article-title":"ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia","volume":"21","author":"Raaijmakers","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0295","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3109\/10428194.2014.907890","article-title":"The role of P-glycoprotein in drug resistance in multiple myeloma","volume":"56","author":"Abraham","year":"2015","journal-title":"Leuk Lymph"},{"issue":"10","key":"10.1016\/j.cca.2026.121066_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26104701","article-title":"P-glycoprotein as a therapeutic target in hematological malignancies: a challenge to overcome","volume":"26","author":"\u00c1lvarez-Carrasco","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0305","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1074-7613(00)80011-4","article-title":"Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells","volume":"10","author":"Catlett-Falcone","year":"1999","journal-title":"Immunity"},{"issue":"41","key":"10.1016\/j.cca.2026.121066_bb0310","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1038\/sj.onc.1204733","article-title":"The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of mcl-1 through a PI 3-K\/Akt pathway","volume":"20","author":"Wei","year":"2001","journal-title":"Oncogene"},{"issue":"36","key":"10.1016\/j.cca.2026.121066_bb0315","doi-asserted-by":"crossref","first-page":"27845","DOI":"10.1074\/jbc.M003428200","article-title":"SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells","volume":"275","author":"Chauhan","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"37","key":"10.1016\/j.cca.2026.121066_bb0320","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1038\/sj.onc.1205664","article-title":"Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1\/Akt signaling in human multiple myeloma cells: therapeutic implications","volume":"21","author":"Mitsiades","year":"2002","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0325","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1038\/bcj.2015.3","article-title":"B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?","volume":"5","author":"Hengeveld","year":"2015","journal-title":"Blood Cancer J."},{"issue":"Supplement 1","key":"10.1016\/j.cca.2026.121066_bb0330","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-187613","article-title":"Drug resistance can be overcome in multiple myeloma and acute myeloid leukemia by targeting mcl-1 with the small chemical KS18","volume":"142","author":"Al-Odat","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121066_bb0335","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0305-7372(03)00077-X","article-title":"The tumor microenvironment: focus on myeloma","volume":"29","author":"Dalton","year":"2003","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.cca.2026.121066_bb0340","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.4049\/jimmunol.168.5.2544","article-title":"Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines","volume":"168","author":"Shain","year":"2002","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.cca.2026.121066_bb0345","first-page":"4139","article-title":"BTK induces CAM-DR through regulation of CXCR4 degradation in multiple myeloma","volume":"11","author":"Wang","year":"2019","journal-title":"Am. J. Transl. Res."},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0350","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.36922\/arnm.1667","article-title":"Fibroblast activation protein-targeted radioligand therapy in various types of cancer: background, clinical studies, and future development","volume":"1","author":"Pang","year":"2023","journal-title":"Adv Radiother Nucl Med"},{"issue":"7","key":"10.1016\/j.cca.2026.121066_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19072087","article-title":"Towards molecular profiling in multiple myeloma: a literature review and early indications of its efficacy for informing treatment strategies","volume":"19","author":"Willenbacher","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0360","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1186\/s12885-019-6446-y","article-title":"Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM)","volume":"19","author":"Huang","year":"2019","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11060463","article-title":"Review of Venetoclax in CLL, AML and multiple myeloma","volume":"11","author":"Lasica","year":"2021","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0370","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.18243","article-title":"How do we manage t(11;14) plasma cell disorders with venetoclax?","volume":"199","author":"Chakraborty","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"22","key":"10.1016\/j.cca.2026.121066_bb0375","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0380","article-title":"Therapeutic potential of Venetoclax and Selinexor in targeting hypoxia-induced vulnerabilities in multiple myeloma","volume":"8","author":"Okabe","year":"2025","journal-title":"Cancer Rep (Hoboken)"},{"issue":"8","key":"10.1016\/j.cca.2026.121066_bb0385","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ni.2060","article-title":"Inflammation meets cancer, with NF-\u03baB as the matchmaker","volume":"12","author":"Ben-Neriah","year":"2011","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.cca.2026.121066_bb0390","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.18632\/oncotarget.3545","article-title":"Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0395","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12964-023-01433-5","article-title":"Interplay between proteasome inhibitors and NF-\u03baB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors","volume":"22","author":"Pakjoo","year":"2024","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0400","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","article-title":"BET proteins as targets for anticancer treatment","volume":"8","author":"Stathis","year":"2018","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.cca.2026.121066_bb0405","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1248\/bpb.b12-00527","article-title":"The conserved 12-amino acid stretch in the inter-bromodomain region of BET family proteins functions as a nuclear localization signal","volume":"35","author":"Fukazawa","year":"2012","journal-title":"Biol. Pharm. Bull."},{"issue":"3","key":"10.1016\/j.cca.2026.121066_bb0410","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/pr050430u","article-title":"Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines","volume":"5","author":"Denis","year":"2006","journal-title":"J. Proteome Res."},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0415","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.cca.2026.121066_bb0420","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.292","article-title":"Post-translational modifications of histones: mechanisms, biological functions, and therapeutic targets","volume":"4","author":"Liu","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.cca.2026.121066_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129742","article-title":"Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy","volume":"104","author":"Dai","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.cca.2026.121066_bb0430","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.onc.1205108","article-title":"Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling","volume":"21","author":"Deroanne","year":"2002","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0435","doi-asserted-by":"crossref","DOI":"10.4081\/hr.2009.e9","article-title":"Histone deacetylase inhibitors in multiple myeloma","volume":"1","author":"Deleu","year":"2009","journal-title":"Hematol. Rep."},{"issue":"5","key":"10.1016\/j.cca.2026.121066_bb0440","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ijc.32020","article-title":"Molecular mechanisms of resistance to CDK4\/6 inhibitors in breast cancer: a review","volume":"145","author":"Pandey","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0445","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0377-1237(06)80055-9","article-title":"Evaluation of suspected monoclonal Gammopathies: experience in a tertiary care hospital","volume":"62","author":"Chopra","year":"2006","journal-title":"Med. J. Armed Forces India"},{"issue":"9","key":"10.1016\/j.cca.2026.121066_bb0450","first-page":"1458","article-title":"The role of serum protein electrophoresis in the detection of multiple myeloma: an experience of a corporate hospital","volume":"6","author":"Tripathy","year":"2012","journal-title":"J. Clin. Diagn. Res."},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0455","article-title":"Relevance of prescribing serum immunofixation electrophoresis in the diagnosis of monoclonal gammopathies","volume":"17","author":"Fadili","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.cca.2026.121066_bb0460","doi-asserted-by":"crossref","DOI":"10.5935\/1676-2444.20150057","article-title":"Comparison between immunofixation and electrophoresis for the early detection of relapsed multiple myeloma","volume":"51","author":"Aita","year":"2015","journal-title":"J. Bras. Patol. Med. Lab."},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0465","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an international myeloma working group mass spectrometry committee report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cca.2026.121066_bb0470","doi-asserted-by":"crossref","DOI":"10.1093\/clinchem\/hvad053","article-title":"Utilizing mass spectrometry to detect and isotype monoclonal proteins in urine: comparison to electrophoretic methods","volume":"69","author":"Moonen","year":"2023","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0475","article-title":"Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma","volume":"15","author":"Zhou","year":"2024","journal-title":"Discov. Oncol."},{"issue":"3","key":"10.1016\/j.cca.2026.121066_bb0480","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/labmed2030013","article-title":"Monoclonal protein evaluation in the diagnostic algorithm for cardiac amyloidosis","volume":"2","author":"Bukhari","year":"2025","journal-title":"LabMed"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0485","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12943-022-01526-8","article-title":"Proteomics technologies for cancer liquid biopsies","volume":"21","author":"Ding","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0490","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s43586-022-00175-x","article-title":"Liquid chromatography-tandem mass spectrometry for clinical diagnostics","volume":"2","author":"Thomas","year":"2022","journal-title":"Nat. Rev. Methods Primers"},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0495","doi-asserted-by":"crossref","DOI":"10.1093\/jalm\/jfaf133","article-title":"The transformative role of mass spectrometry in diagnosing and monitoring monoclonal Gammopathies and plasma cell disorders","volume":"10","author":"Garc\u00eda de la Rosa","year":"2025","journal-title":"J Appl Lab Med"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","article-title":"Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma","volume":"13","author":"Mai","year":"2023","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.cca.2026.121066_bb0505","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1021\/acs.jproteome.0c01022","article-title":"Mass spectrometry provides a highly sensitive noninvasive means of sequencing and tracking M-protein in the blood of multiple myeloma patients","volume":"20","author":"McDonald","year":"2021","journal-title":"J. Proteome Res."},{"issue":"3","key":"10.1016\/j.cca.2026.121066_bb0510","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.jproteome.7b00890","article-title":"Development of a targeted mass-spectrometry serum assay to quantify M-protein in the presence of therapeutic monoclonal antibodies","volume":"17","author":"Zajec","year":"2018","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.cca.2026.121066_bb0515","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clinbiochem.2017.08.013","article-title":"Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences","volume":"51","author":"McCudden","year":"2018","journal-title":"Clin. Biochem."},{"issue":"16","key":"10.1016\/j.cca.2026.121066_bb0520","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70128","article-title":"Impact of M-protein detection on the response evaluations of patients undergoing treatment with the IgG-\u03ba monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents","volume":"13","author":"Shirouchi","year":"2024","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.cca.2026.121066_bb0525","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1515\/cclm-2023-0781","article-title":"M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator","volume":"62","author":"Wijnands","year":"2024","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0530","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17010135","article-title":"Monitoring M-protein, therapeutic antibodies, and polyclonal antibodies in a multiparametric mass spectrometry assay provides insight into therapy response kinetics in patients with multiple myeloma","volume":"17","author":"Wijnands","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0535","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/imr.12659","article-title":"Immunoglobulin gene analysis as a tool for investigating human immune responses","volume":"284","author":"Dunn-Walters","year":"2018","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0540","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12672-025-01816-9","article-title":"Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions","volume":"16","author":"Ghoreyshi","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.cca.2026.121066_bb0545","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.932852","article-title":"Minimal residual disease detection by next-generation sequencing in multiple myeloma: promise and challenges for response-adapted therapy","volume":"12","author":"Ferla","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2026.121066_bb0550","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-143093","article-title":"Role of clonoSEQ\u00ae, a next-generation sequencing (NGS) assay and PET\/CT as a measure of minimal residual disease negativity among patients with multiple myeloma","volume":"136","author":"Nooka","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0555","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0560","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/leu.2015.7","article-title":"The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution","volume":"29","author":"Puig","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.cca.2026.121066_bb0565","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0570","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.16362","article-title":"Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia","volume":"188","author":"Ghannam","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"26","key":"10.1016\/j.cca.2026.121066_bb0575","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.cca.2026.121066_bb0580","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkz474","article-title":"High efficiency error suppression for accurate detection of low-frequency variants","volume":"47","author":"Wang","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0585","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-024-03470-7","article-title":"Enhancing mutation detection in multiple myeloma with an error-corrected ultra-sensitive NGS assay without plasma cell enrichment","volume":"24","author":"Kim","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.cca.2026.121066_bb0590","doi-asserted-by":"crossref","DOI":"10.4103\/2394-4722.158803","article-title":"Role of circulating tumor cells in future diagnosis and therapy of cancer","volume":"1","author":"Potdar","year":"2015","journal-title":"J. Cancer Metastasis Treat."},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0595","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1758834010378414","article-title":"Circulating tumour cells: their utility in cancer management and predicting outcomes","volume":"2","author":"Krebs","year":"2010","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0600","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.canlet.2006.12.014","article-title":"Circulating tumor cells (CTC) detection: clinical impact and future directions","volume":"253","author":"Paterlini-Brechot","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cca.2026.121066_bb0605","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/617421","article-title":"Significance of circulating tumor cells detected by the CellSearch System in patients with metastatic breast colorectal and prostate cancer","volume":"2010","author":"Miller","year":"2010","journal-title":"J. Oncol."},{"issue":"8","key":"10.1016\/j.cca.2026.121066_bb0610","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00432-011-0988-y","article-title":"Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance","volume":"137","author":"Sun","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.cca.2026.121066_bb0615","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.22.01226","article-title":"More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia\u2013Like Multiple Myeloma","volume":"41","author":"Jelinek","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.cca.2026.121066_bb0620","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.cca.2026.121066_bb0625","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0630","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ejh.12986","article-title":"Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11; 14)","volume":"100","author":"Gonsalves","year":"2018","journal-title":"Eur. J. Haematol."},{"issue":"11","key":"10.1016\/j.cca.2026.121066_bb0635","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0640","doi-asserted-by":"crossref","DOI":"10.3390\/ph18020159","article-title":"Minimal residual disease significance in multiple myeloma patients treated with anti-CD38 monoclonal antibodies","volume":"18","author":"Caroni","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"12","key":"10.1016\/j.cca.2026.121066_bb0645","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0650","doi-asserted-by":"crossref","first-page":"23742","DOI":"10.1038\/s41598-024-75636-2","article-title":"CD27 is not an ideal marker for human memory B cells and can be modulated by IL-21 upon stimulated by anti-CD40","volume":"14","author":"Kang","year":"2024","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.cca.2026.121066_bb0655","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3892\/etm.2025.12814","volume":"29","author":"Loderer","year":"2025","journal-title":"Exp. Ther. Med."},{"issue":"10","key":"10.1016\/j.cca.2026.121066_bb0660","doi-asserted-by":"crossref","DOI":"10.3390\/diseases13100320","article-title":"Applications of multiparameter flow cytometry in the diagnosis, prognosis, and monitoring of multiple myeloma patients","volume":"13","author":"Leonardos","year":"2025","journal-title":"Diseases"},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0665","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/j.clml.2025.01.010","article-title":"Minimal residual disease testing infrastructure in multiple myeloma: guidance for clinical trial and routine practice use in Canada","volume":"25","author":"Mian","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"19","key":"10.1016\/j.cca.2026.121066_bb0670","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics15192425","article-title":"Next-generation sequencing: a review of its transformative impact on cancer diagnosis, treatment, and resistance management","volume":"15","author":"Isaic","year":"2025","journal-title":"Diagnostics"},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0675","doi-asserted-by":"crossref","DOI":"10.1002\/mbo3.70104","article-title":"Next-generation sequencing in infectious-disease diagnostics: economic, regulatory, and clinical pathways to adoption","volume":"14","author":"Osei Sekyere","year":"2025","journal-title":"Microbiologyopen"},{"issue":"9","key":"10.1016\/j.cca.2026.121066_bb0680","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jmoldx.2021.06.005","article-title":"Next-generation sequencing\u2013based clonality assessment of Ig gene rearrangements: A multicenter validation study by EuroClonality-NGS","volume":"23","author":"van den Brand","year":"2021","journal-title":"J. Mol. Diagn."},{"issue":"11","key":"10.1016\/j.cca.2026.121066_bb0685","doi-asserted-by":"crossref","first-page":"e586","DOI":"10.1016\/S1470-2045(25)00426-7","volume":"26","author":"Sanz","year":"2025","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.cca.2026.121066_bb0690","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/leu.2016.46","article-title":"Pre- and post-transplant quantification of measurable (\u2019minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia","volume":"30","author":"Zhou","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0695","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/gcc.23023","article-title":"Computational methods and translational applications for targeted next-generation sequencing platforms","volume":"61","author":"Luthra","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.cca.2026.121066_bb0700","article-title":"The use of next-generation sequencing in personalized medicine","author":"Popova","year":"2024","journal-title":"ArXiv"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0705","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/jha2.633","article-title":"Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal\/measurable residual disease in autografts of patients with multiple myeloma","volume":"4","author":"Urushihara","year":"2023","journal-title":"EJHaem"},{"key":"10.1016\/j.cca.2026.121066_bb0710","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.820605","article-title":"The utility of Euroflow MRD assessment in real-world multiple myeloma practice","volume":"12","author":"Turner","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0715","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-026-01508-9","article-title":"Peripheral blood cfDNA detection using clonoSEQ assay in multiple myeloma is concordant with bone marrow and clinical biomarkers","volume":"16","author":"Wiedmeier-Nutor","year":"2026","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.cca.2026.121066_bb0720","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.cca.2026.121066_bb0725","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2024-210171","article-title":"MRD by flow cytometry and FDG-PET\/CT for the post-induction response assessment in patients with multiple myeloma treated in the phase 3 GMMG HD7 study","volume":"144","author":"Hajiyianni","year":"2024","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.cca.2026.121066_bb0730","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.cca.2026.121066_bb0735","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.cca.2026.121066_bb0740","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V126.23.391.391","article-title":"Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe francophone Du Myelome (IFM\/DFCI 2009 trial)","volume":"126","author":"Attal","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0745","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0750","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.cca.2026.121066_bb0755","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cca.2026.121066_bb0760","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s40265-025-02232-7","article-title":"Minimal residual disease negativity as the primary goal of multiple myeloma therapy","volume":"85","author":"Cooperrider","year":"2025","journal-title":"Drugs"},{"issue":"Suppl","key":"10.1016\/j.cca.2026.121066_bb0765","article-title":"Minimal residual disease (mrd) in multiple myeloma: prognostic and therapeutic implications (including imaging)","volume":"3","author":"Owen","year":"2019","journal-title":"Hemasphere"},{"issue":"24","key":"10.1016\/j.cca.2026.121066_bb0770","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1182\/bloodadvances.2020002811","article-title":"Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.cca.2026.121066_bb0775","doi-asserted-by":"crossref","DOI":"10.2217\/ijh-2020-0018","article-title":"Minimal residual disease in multiple myeloma: are we there yet?","volume":"9","author":"Devarakonda","year":"2020","journal-title":"Int. J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0780","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41408-024-01102-x","article-title":"Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence","volume":"14","author":"Martinez-Lopez","year":"2024","journal-title":"Blood Cancer J."},{"issue":"19","key":"10.1016\/j.cca.2026.121066_bb0785","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/CM9.0000000000003655","article-title":"Redefining multiple myeloma treatment: advances, challenges, and future directions in immunotherapy","volume":"138","author":"Fu","year":"2025","journal-title":"Chin Med J (Engl)"},{"issue":"19","key":"10.1016\/j.cca.2026.121066_bb0790","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.3390\/cancers16193288","article-title":"Measurable residual disease testing in multiple myeloma following T-cell redirecting therapies","volume":"16","author":"Shim","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2026.121066_bb0795","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.720692","article-title":"Chimeric antigen receptor-T cells: a pharmaceutical scope","volume":"12","author":"Hern\u00e1ndez-L\u00f3pez","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0800","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"issue":"12","key":"10.1016\/j.cca.2026.121066_bb0805","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123081","article-title":"CD28 and 41BB costimulatory domains alone or in combination differentially influence cell surface dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T cells","volume":"15","author":"Mez\u0151si-Csapl\u00e1r","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cca.2026.121066_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113392","article-title":"Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies","volume":"144","author":"Sun","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0815","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1186\/s12967-025-06857-w","article-title":"Discordant CAR-T cell signaling: implications of divergence from physiological T cell activation","volume":"23","author":"Gonzalez-Garcia","year":"2025","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.cca.2026.121066_bb0820","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.84","article-title":"TRUCKS, the fourth-generation CAR T cells: current developments and clinical translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Adv Cell Gene Ther"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0825","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-025-01746-7","article-title":"Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution","volume":"18","author":"Chen","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.cca.2026.121066_bb0830","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in Lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0835","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.cca.2026.121066_bb0840","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jcyt.2022.01.004","article-title":"Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials","volume":"24","author":"Stewart","year":"2022","journal-title":"Cytotherapy"},{"issue":"17","key":"10.1016\/j.cca.2026.121066_bb0845","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70069","article-title":"Cytokine release syndrome in solid tumors","volume":"131","author":"Synnott","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2026.121066_bb0850","doi-asserted-by":"crossref","DOI":"10.3390\/biom13020382","article-title":"Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0855","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CCM.0000000000005149","article-title":"Critically ill patients treated for chimeric antigen receptor-related toxicity: a multicenter study","volume":"50","author":"Gutierrez","year":"2022","journal-title":"Crit. Care Med."},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0860","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.hoc.2023.05.010","article-title":"Early and late toxicities of chimeric antigen receptor T-cells","volume":"37","author":"Epperly","year":"2023","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"9","key":"10.1016\/j.cca.2026.121066_bb0865","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jcyt.2024.04.075","article-title":"Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors","volume":"26","author":"Miller","year":"2024","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0870","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0875","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/hematology.2024000535","article-title":"Mitigating and managing infection risk in adults treated with CAR T-cell therapy","volume":"2024","author":"Tabbara","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"3","key":"10.1016\/j.cca.2026.121066_bb0880","first-page":"275","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0885","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2378543","article-title":"Approved CAR-T therapies have reproducible efficacy and safety in clinical practice","volume":"20","author":"Goyco Vera","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"issue":"8","key":"10.1016\/j.cca.2026.121066_bb0890","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10297","key":"10.1016\/j.cca.2026.121066_bb0895","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.cca.2026.121066_bb0900","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0905","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/2643-3230.BCD-20-0122","article-title":"Dual targeting with CAR T cells to limit antigen escape in multiple myeloma","volume":"1","author":"Simon","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb0910","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0915","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol. Ther."},{"issue":"19","key":"10.1016\/j.cca.2026.121066_bb0920","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u0393-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cca.2026.121066_bb0925","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cca.2026.121066_bb0930","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.832645","article-title":"Armored BCMA CAR T cells eliminate multiple myeloma and are resistant to the suppressive effects of TGF-\u03b2","volume":"13","author":"Alabanza","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0935","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, Lenalidomide, dexamethasone, and Daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.cca.2026.121066_bb0940","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1158\/2643-3230.BCD-23-0134","article-title":"MRD and plasma cell dynamics after CAR T-cell therapy in myeloma","volume":"4","author":"Landgren","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0945","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-023-00820-y","article-title":"Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma","volume":"13","author":"Bansal","year":"2023","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0950","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10238-025-01965-9","article-title":"AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions","volume":"26","author":"Hsu","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.cca.2026.121066_bb0955","doi-asserted-by":"crossref","DOI":"10.3389\/frhem.2024.1331109","article-title":"How artificial intelligence revolutionizes the world of multiple myeloma","volume":"3","author":"Romero","year":"2024","journal-title":"Front. Hematol."},{"issue":"6","key":"10.1016\/j.cca.2026.121066_bb0960","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1109\/TCBB.2020.2973148","article-title":"FUNMarker: fusion network-based method to identify prognostic and heterogeneous breast cancer biomarkers","volume":"18","author":"Li","year":"2020","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinform."},{"issue":"15","key":"10.1016\/j.cca.2026.121066_bb0965","doi-asserted-by":"crossref","DOI":"10.3390\/electronics14153014","article-title":"Machine learning-based predictive model for risk stratification of multiple myeloma from monoclonal gammopathy of undetermined significance","volume":"14","author":"Santamar\u00eda","year":"2025","journal-title":"Electronics"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0970","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41408-023-00798-7","article-title":"Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance","volume":"13","author":"Ryu","year":"2023","journal-title":"Blood Cancer J."},{"issue":"Supplement 1","key":"10.1016\/j.cca.2026.121066_bb0975","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1182\/blood-2022-168119","article-title":"Artificial intelligence-enhanced models to predict light chain amyloidosis from patients with monoclonal Gammopathy of undetermined significance and smoldering multiple myeloma","volume":"140","author":"Muchtar","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121066_bb0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.scib.2025.11.027","article-title":"A novel deep learning system for STEMI prognostic prediction from multi-sequence cardiac magnetic resonance","author":"Chen","year":"2025","journal-title":"Sci. Bull."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0985","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41408-024-01172-x","article-title":"Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages","volume":"14","author":"Cheng","year":"2024","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb0990","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s12920-021-01140-5","article-title":"Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways","volume":"14","author":"Ortiz-Est\u00e9vez","year":"2021","journal-title":"BMC Med. Genomics"},{"key":"10.1016\/j.cca.2026.121066_bb0995","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2024.1452558","article-title":"Preliminary screening of biomarkers and drug candidates in a mouse model of \u03b2-thalassemia based on quasi-targeted metabolomics","volume":"15","author":"Guo","year":"2024","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb1000","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/s12967-025-06856-x","article-title":"Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies","volume":"23","author":"Salvati","year":"2025","journal-title":"J. Transl. Med."},{"issue":"18","key":"10.1016\/j.cca.2026.121066_bb1005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17183045","article-title":"Computational drug repurposing across the multiple myeloma Spectrum: from MGUS to MM","volume":"17","author":"Savva","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.cca.2026.121066_bb1010","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.cca.2026.121066_bb1015","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1462307","article-title":"The current socioeconomic and regulatory landscape of immune effector cell therapies","volume":"11","author":"Sainatham","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.cca.2026.121066_bb1020","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape\u2014lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol Ther Meth Clin Dev"},{"key":"10.1016\/j.cca.2026.121066_bb1025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1397613","article-title":"Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma","volume":"14","author":"Medina-Olivares","year":"2024","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb1030","first-page":"10","article-title":"Challenges in global access to CAR-T cells: an Asian perspective","volume":"7","author":"Hwang","year":"2024","journal-title":"Blood Cell Ther"},{"issue":"3","key":"10.1016\/j.cca.2026.121066_bb1035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3343\/alm.2023.0388","article-title":"Current challenges in chimeric antigen receptor T-cell therapy in patients with B-cell lymphoid malignancies","volume":"44","author":"Kim","year":"2024","journal-title":"Ann. Lab. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb1040","doi-asserted-by":"crossref","DOI":"10.1186\/s13036-026-00666-5","article-title":"Are we there yet? The road to faster and more efficient CAR T cell manufacturing","volume":"20","author":"Matos","year":"2026","journal-title":"J. Biol. Eng."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb1045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s44272-025-00050-2","article-title":"Advances in CAR-T cell therapy for refractory diseases: challenges, innovations, clinical breakthroughs, and future prospects","volume":"4","author":"Liao","year":"2025","journal-title":"Clin. Cancer Bull."},{"issue":"7","key":"10.1016\/j.cca.2026.121066_bb1050","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph22071059","article-title":"Unequal gains? A literature review on the Affordable Care Act's effects on healthcare utilization across racial and ethnic groups","volume":"22","author":"Osmani","year":"2025","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"12","key":"10.1016\/j.cca.2026.121066_bb1055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009611","article-title":"CAR-T cell therapy in developing countries: how long should we wait?","volume":"12","author":"Gautam","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"10315","key":"10.1016\/j.cca.2026.121066_bb1060","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/S0140-6736(21)00673-5","article-title":"The lancet commission on diagnostics: transforming access to diagnostics","volume":"398","author":"Fleming","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cca.2026.121066_bb1065","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2022016204","article-title":"Genome-edited allogeneic donor \u201cuniversal\u201d chimeric antigen receptor T cells","volume":"141","author":"Qasim","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb1070","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"Jo","year":"2022","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.cca.2026.121066_bb1075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00262-025-04106-z","article-title":"Precision sniper for solid tumors: CAR-NK cell therapy","volume":"74","author":"Li","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"10.1016\/j.cca.2026.121066_bb1080","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1078-0432.CCR-23-1872","article-title":"Cooperative armoring of CAR and TCR T cells by T cell-restricted IL15 and IL21 universally enhances solid tumor efficacy","volume":"30","author":"Nguyen","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cca.2026.121066_bb1085","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104912","article-title":"Beyond CAR-T: engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy","volume":"214","author":"Zhang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"11","key":"10.1016\/j.cca.2026.121066_bb1090","article-title":"Multiplexed iPSC platform for advanced NK cell immunotherapies","volume":"6","author":"Kumar","year":"2025","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb1095","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00432-025-06393-6","article-title":"Phage therapy and the microbiome in hematologic malignancies: opportunities, mechanisms, and early evidence","volume":"152","author":"Zhang","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb1100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2023.108557","article-title":"Harnessing bacteria for tumor therapy: current advances and challenges","volume":"35","author":"Guo","year":"2024","journal-title":"Chin. Chem. Lett."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb1105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","article-title":"Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer","volume":"14","author":"Lyu","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.121066_bb1110","article-title":"Next-generation CAR-T and CAR-NK cell therapies in hematologic malignancies: engineering for persistence, specificity, and safety","volume":"17","author":"Al-khreisat","year":"2026","journal-title":"Discover Oncol."},{"issue":"2","key":"10.1016\/j.cca.2026.121066_bb1115","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PPO.0000000000000511","article-title":"Off-the-shelf chimeric antigen receptor T cells: how do we get there?","volume":"27","author":"Watanabe","year":"2021","journal-title":"Cancer J."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126002482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126002482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:28:36Z","timestamp":1783643316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126002482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":223,"alternative-id":["S0009898126002482"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121066","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"121066"}}